Washington, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                                 Date of Report
                       (Date of earliest event reported):

                                November 3, 2003

                                 ANTIGENICS INC.
             (Exact name of registrant as specified in its charter)

 DELAWARE              000-29089                       06-1562417

(State or other   (Commission file number)  (I.R.S. Employer Identification No.)
jurisdiction of
incorporation of

                          630 FIFTH AVENUE, SUITE 2100
                            NEW YORK, NEW YORK 10111
              (Address of principal executive offices and zip code)

                                 (212) 994-8200
              (Registrant's telephone number, including area code)

Item 5.         Other Events and Regulation FD Disclosure

     On November 3, 2003,  Antigenics  Inc.  announced that Renu Gupta,  MD, has
joined the company as senior vice president of development,  a new position that
will be responsible for regulatory affairs,  clinical  development,  and program
and  portfolio   management.   Antigenics  also  announced   changes  in  senior
management. As of April 1, 2004, Elma Hawkins, PhD, currently the company's vice
chairman, will become senior advisor to the CEO. In addition,  Antigenics' chief
medical   officer   Jonathan  Lewis,   MD,  PhD,  has  left  the  company.   The
responsibilities  of Drs. Hawkins and Lewis will be absorbed within  Antigenics'
newly  restructured  senior  management team. The full text of the press release
issued in connection  with the  announcement is attached as Exhibit 99.1 to this
current report on Form 8-K.

Item 7.         Financial Statements and Exhibits.

(c) Exhibits:

99.1            Press Release dated November 3, 2003


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                          ANTIGENICS INC.

Date: November 3, 2003                            By:  /s/ Garo H. Armen
                                                    Garo H. Armen, Ph.D.
                                    Chairman and Chief Executive Officer

                                  EXHIBIT INDEX

The following designated exhibits are filed herewith:


99.1              Press Release dated November 3, 2003